Urothelial Carcinoma Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The urothelial carcinoma treatment market size has grown rapidly in recent years. It will grow from $2.86 billion in 2024 to $3.37 billion in 2025 at a compound annual growth rate (CAGR) of 18%. The growth in the historic period can be attributed to rising prevalence of urothelial carcinoma, growing awareness of urothelial carcinoma, increasing access to healthcare, rising disposable incomes.

The urothelial carcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $6.22 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to aging population, demand for personalized medicine, rising government support for urothelial carcinoma research and treatment, growing investments on urothelial carcinoma treatment. Major trends in the forecast period include biomarker-driven therapies, neoadjuvant and adjuvant approaches, liquid biopsies, minimally invasive surgeries, chemotherapy development, digital health technologies.

The growing incidence of bladder cancer is expected to drive the expansion of the urothelial carcinoma treatment market in the future. Bladder cancer is a common cancer that affects the cells lining the urinary bladder, leading to the need for a variety of treatment options for patients and healthcare providers. Research into bladder cancer helps inform targeted therapies and enhances understanding of urothelial carcinoma, promoting cross-disciplinary approaches to improve treatment outcomes. For example, in September 2023, the National Library of Medicine, a U.S.-based medical library operated by the federal government, projected that the number of new bladder cancer (BCa) cases would reach 991,000 by 2040, reflecting a 72.8% increase from 2020. Annual BCa-related deaths are also expected to rise to 397,000, marking an 86.6% increase. As a result, the growing incidence of bladder cancer will drive the urothelial carcinoma treatment market.

The growing demand for chemotherapy is anticipated to be a significant driver for the growth of the urothelial carcinoma treatment market in the foreseeable future. Chemotherapy is a medical treatment that employs drugs to target and eradicate rapidly dividing cells within the body, commonly employed in cancer treatment. Chemotherapy's pivotal role stems from its effectiveness in managing various stages of the disease, making it an integral approach in urothelial carcinoma treatment. For instance, as of June 2023, Mesothelioma.com, a medical information provider based in the United States, reports that approximately 25% of cancer patients in the US receive chemotherapy each year. Hence, the increasing demand for chemotherapy is set to propel the urothelial carcinoma treatment market.

The prominent companies operating in the urothelial carcinoma treatment market are actively dedicated to introducing innovative products to enhance their competitive positions and meet the changing needs of their customers. For example, in March 2023, Nonacus Limited, a UK-based medical product manufacturer, unveiled GALEAS Bladder, a cutting-edge diagnostic test designed for the non-invasive detection of bladder cancer. GALEAS Bladder represents a significant advancement in bladder cancer diagnostics, offering a comprehensive molecular triage solution that seamlessly moves from sample collection to the final diagnostic report. It leverages a molecular biomarker with exceptional sensitivity to quickly and accurately identify bladder cancer, simplifying the diagnostic process and reducing the necessity for invasive procedures like cystoscopies. Developed in partnership with the University of Birmingham in the UK, GALEAS Bladder has undergone rigorous validation, involving over 600 patient samples from three distinct clinical cohorts in the UK. This extensive assessment underscores the remarkable performance of GALEAS Bladder, delivering high diagnostic accuracy (with a sensitivity exceeding 90% and specificity over 85%) and effectively catering to varying bladder cancer grades and stages.

In September 2024, A. Menarini Diagnostics, an Italy-based pharmaceutical company, entered into a partnership with Nucleix to enhance product marketing. As part of this collaboration, A. Menarini Diagnostics will assume exclusive marketing rights for the non-invasive Bladder EpiCheck test across Europe in the coming months. This urine test will provide patients and clinicians with an effective tool for detecting and monitoring the recurrence of bladder cancer and upper tract urothelial carcinoma (UTUC). Nucleix, an Israel-based company, specializes in the development and sale of non-invasive cancer tests.

Major companies operating in the urothelial carcinoma treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., GlaxoSmithKline PLC, Astellas Pharma Inc., Agilent Technologies Inc., Eisai Co. Ltd., Incyte Corporation, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Seagen Inc., Lupin Limited, Genentech Inc., UroGen Pharma Inc., Acerta Pharma B.V., Asieris Pharmaceuticals Co. Ltd., Pacific Edge Limited, Protara Therapeutics Inc., Hamlet Pharma AB, CG Oncology Inc., AroCell AB, ImmunityBio Inc., IDL Biotech AB.

North America was the largest region in the urothelial carcinoma treatment market in 2024. The regions covered in urothelial carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urothelial carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urothelial carcinoma treatment market consists of revenues earned by entities by providing transurethral resection (TURBT) surgery and external beam radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The urothelial carcinoma treatment market also includes sales of platinum-based chemotherapy drugs such as cisplatin or carboplatin and immune checkpoint inhibitor drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Urothelial carcinoma is a form of cancer that originates in the urothelial cells lining the interior of the urinary system, encompassing the bladder, ureters (connecting tubes between the kidneys and the bladder), and the renal pelvis (the kidney segment responsible for collecting urine). Treatments for urothelial carcinoma, involving both surgical procedures and intravenous therapies, play a crucial role in managing the disease, enhancing patient outcomes, and improving their quality of life.

The primary categories of urothelial carcinoma treatment are non-invasive and invasive. Non-invasive treatment pertains to addressing early-stage bladder cancer that has not spread to the deeper layers of the bladder or surrounding tissues. This is achieved through techniques like transurethral resection of bladder tumors (TURBT), which entails the removal of cancerous tissue from the bladder lining, and intravesical therapies, where medications are directly delivered into the bladder to prevent recurrence. These treatments, encompassing immunotherapy, radiotherapy, and chemotherapy, are also employed to address various types of urinary system cancers, including bladder, urethral, ureteric, and renal pelvic cancers. These treatments serve a variety of end users, including hospitals, homecare services, specialty centers, and others.

The urothelial carcinoma treatment market research report is one of a series of new reports that provides urothelial carcinoma treatment market statistics, including urothelial carcinoma treatment industry global market size, regional shares, competitors with a urothelial carcinoma treatment market share, detailed urothelial carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the urothelial carcinoma treatment industry. This urothelial carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.